Atomo Diagnostics Limited (ASX: AT1)

Market Cap	12.78M
Revenue (ttm)	4.09M
Net Income (ttm)	-6.85M
Shares Out	639.20M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,761
Open	0.0220
Previous Close	0.0210
Day's Range	0.0200 - 0.0220
52-Week Range	0.0180 - 0.0600
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2024

About Atomo Diagnostics

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers rapid diagnostic test devices for HIV screening, pregnancy test, and respiratory test. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 85
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AT1

Financial Performance

In 2024, Atomo Diagnostics's revenue was 4.09 million, an increase of 60.65% compared to the previous year's 2.54 million. Losses were -6.85 million, -31.23% less than in 2023.